Red Yeast Rice

Red yeast rice is not a gentle natural alternative to statins; it is a statin, sold without dose standardisation. Monascus purpureus fermentation produces monacolin K, a molecule structurally identical to lovastatin, and this is entirely responsible for the cholesterol effect. Meta-analyses of randomised trials report LDL reductions of roughly 15-25%, and the Chinese Coronary Secondary Prevention Study, a large trial using a red yeast rice preparation, found reduced recurrent coronary events and mortality over about four years — outcome data most supplements never approach. The problems are pharmaceutical rather than botanical. Independent analyses of commercial products have found monacolin K content varying from negligible to more than 10 mg per daily dose, meaning two bottles labelled the same can deliver very different statin doses. Some products have been contaminated with citrinin, a nephrotoxic mycotoxin. And because it is a statin, it produces statin adverse effects: myalgia, raised liver enzymes and, rarely, rhabdomyolysis, along with all the statin drug interactions. The European Food Safety Authority concluded it could not establish a safe monacolin intake, and the EU now caps monacolin content in supplements at under 3 mg. For most people with elevated cholesterol, a prescribed statin at a known dose with monitoring is the more rational choice.